类似儿童方案治疗PH染色体阴性青少年及年轻成人急性淋巴细胞白血病：一项单中心回顾性研究

OBJECTIVE: To investigate the efficacy of using a pediatric-inspired regimen for adolescents and young adults（AYA）with Philadelphia chromosome-negative（Ph(−)）acute lymphoblastic leukemia/lymphoblastic lymphoma（ALL/LBL）at a single center in China. METHODS: Clinical data of 71 consecutive newly diagnosed AYA patients with Ph(−)ALL/LBL on a pediatric-inspired regimen in Peking Union Medical College Hospital from January 2012 to November 2018 were retrospectively analyzed. RESULTS: Median age at diagnosis was 20 years（range: 15–38）, and 46 patients（64.8%）were male. Forty-nine（69.0%）had B-ALL/LBL. Among 62 ALL patients, 22（35.5%）were high-risk.complete remission rate was 93.0%. At follow-up with a median time of 44 months, the estimated 5-year disease-free survival（DFS）and overall survival（OS）was 56.3%and 64.3%, respectively. There was no significant difference in 5-year OS between allogeneic hematopoietic stem cell transplantation group and the continuous chemotherapy group after completion of 4 courses of chemotherapy. The 5-year DFS and OS for the non-high-risk group was 63.1%and 73.7%, respectively, which were significantly higher than 32.0%and 44.4%for the high-risk group, respectively（P<0.001）. CONCLUSION: The use of pediatric-inspired regimen for AYAs with Ph(−)ALL/LBL was feasible and effective.